Favorable Media Coverage Somewhat Unlikely to Affect Geron Corporation (GERN) Stock Price

In the last earnings report the EPS was $-0.18 with 159.23M shares now outstanding.

Geron Corporation (NASDAQ:GERN) shares traded -5.34% down during most recent session to reach at the closing price of $1.95. The consensus mean EPS for the current quarter is at $-0.04 derived from a total of 3 estimates from the analysts who have weighed in on projected earnings. During the same period in the prior year, the business posted $0.17 earnings per share. The volume of FRED witnessed a shift from 2.9 million shares, based on a 50-day average, to 0.93 million shares. The firm's revenue for the quarter was down 96.8% on a year-over-year basis. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the stock.

Taking a broader look brokerage firms' analysts on the street with an expectant view have Geron Corporation (NASDAQ:GERN) high price target of $5 and with a conservative view have low price target of $2.5. The company maintains price to book ratio of 3.03 vs.an industry average at 19.02. Zacks Investment Research downgraded Geron Corporation from a "buy" rating to a "hold" rating in a report on Tuesday, July 11th. The company now has an average rating of "Buy" and an average target price of $5.00.

COPYRIGHT VIOLATION NOTICE: "Favorable Media Coverage Somewhat Unlikely to Affect Geron Corporation (GERN) Stock Price" was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this article on another publication, it was illegally copied and reposted in violation of global copyright and trademark legislation.

A number of large investors have recently made changes to their positions in GERN.

Wall Street analysts are predicting that Geron Corporation (NASDAQ:GERN) will report earnings per share of $-0.04 in their quarterly report. TFS Capital LLC bought a new stake in Geron Corp. during the second quarter valued at approximately $145,000. Janney Montgomery Scott LLC boosted its stake in Geron Corp.by 97.0% in the second quarter. Among active positions in the latest quarter, 48 holders increased their positions by a total of 3.05 million shares, 44 holders decreased the positions by a total of 985539 shares, and 35 holders held their positions. California State Teachers Retirement System now owns 240,167 shares worth $524,000. American International Group Inc grew its stake by buying 7,454 shares an increase of 8.1% in the quarter. Accern also gave news coverage about the biopharmaceutical company an impact score of 46.4907050785577 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. Bank of America Corp DE now owns 65,403 shares of the biopharmaceutical company's stock worth $148,000 after buying an additional 13,698 shares during the period. Using its nucleic acid chemistry, Geron designed Imetelstat to be an oligonucleotide that binds with high affinity to the ribonucleic acid (RNA) template of telomerase, thereby directly inhibiting telomerase activity.